What is CHRS's dilution risk score?

CHRS has a latest available DilutionScore record of 72/100, categorized as high dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for CHRS, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for CHRS?

DilutionWatch tracks 25 SEC filing types for CHRS including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect CHRS shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For CHRS, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for CHRS tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for CHRS. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

CHRS Dilution Risk Score: 72/100 (HIGH)

Score Breakdown

📋 Offering Ability

66

💰 Cash Runway

65

📊 Float Risk

17

⚠️ Warrant Exposure

40

🔄 Convertible Debt

85

Dilution Forecast

⛈️

Warning

High probability of dilution event

model est. 48%

🔁 Convertible Conversion model 60%

• Major convertible overhang: 33% potential dilution

• Convertible risk score very high (85/100)

🔄 Reverse Split model est. 40%

• 50-day avg $1.71 approaching $1 threshold

• 6 months cash with weak price

💰 Capital Raise model 33%

• Under 12 months cash (6mo)

• Active ATM program with $50M remaining capacity

🔔 Track CHRS — Get forecast alerts →

Market Data

Market Cap$245.26M

Shares Outstanding154.50M

Float132.53M

Cash$105.31M

Debt$73.66M

Short InterestN/A

Institutional Holdings

QoQ: ↑ 58.0% shares (2026Q1 vs prior)

156 institutional holders · 82.94M shares

#1 BARCLAYS PLC 16.73M shares

#2 VANGUARD CAPITAL MANAGEMENT LLC 10.91M shares

#3 BlackRock, Inc. 10.37M shares

+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest24.53M

Days to Cover53.6

% of Float18.5%

FINRA data as of Jul 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2021-12-31

8-K 8K EVENT 2026-02-17

424B5 ATM 2026-02-13

424B5 ATM 2026-02-12

4 INSIDER TRANSACTION 2026-01-26

Full SEC filing analysis available with free account →

Recent News

No recent news

Factual CHRS Dilution Snapshot

Coherus Oncology, Inc. (CHRS) has a DilutionScore of 72/100, rated High dilution risk. Score date: August 28, 2026.

Stored ATM program remaining capacity: $50.0M.
Recent SEC activity tracked for CHRS: 8-K on 2026-02-17; 424B5 on 2026-02-13; 424B5 on 2026-02-12.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.